Patients with cancers driven by the protein KRAS, which are particularly hard to treat, may benefit from small molecules that attach to and disrupt the function of a KRAS-containing protein complex, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.
Fuente : http://www.eurekalert.org/pub_releases/2013-10/aaf...
Fuente : http://www.eurekalert.org/pub_releases/2013-10/aaf...